Namibia - English - Namibia Medicines Regulatory Council

cipla-medpro (pty) ltd - cyproheptadine hydrochloride - tablet - each tablet contains cyproheptadine hydrochloride equivalent to cyproheptadine 4,0 mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine delayed-release capsules, usp are indicated for the treatment of: - major depressive disorder [see clinical studies 14.1] - generalized anxiety disorder [see clinical studies 14.2] - diabetic peripheral neuropathy [see clinical studies 14.3] - chronic musculoskeletal pain [see clinical studies 14.5] monoamine oxidase inhibitors (maois) — the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine delayed-release capsules, usp are indicated for the treatment of: - major depressive disorder [see clinical studies 14.1] - generalized anxiety disorder [see clinical studies 14.2] - diabetic peripheral neuropathy [see clinical studies 14.3] - chronic musculoskeletal pain [see clinical studies 14.5] monoamine oxidase inhibitors (maois) — the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin

Kenya - English - Pharmacy and Poisons Board

highnoon laboratories limited 17.5 kilometer multan road lahore-53700 pakistan - cyproheptadine orotate carnitine hydrochloride… - syrup - cyproheptadine orotate … - combinations multivitamins: multivitamins with

Namibia - English - Namibia Medicines Regulatory Council

mc pharma (pty) ltd - cyproheptadine hydrochloride - tablet - cyproheptadine hydrochloride tablets 4 mg

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - duloxetine delayed-release capsules are indicated for the treatment of: monoamine oxidase inhibitors (maois) the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)] . pregnancy category c   risk summary there are no adequate and well-controlled studies of duloxetine administration in pregnant women. in animal studie

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride -

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - cyproheptadine hydrochloride - tablets - 4 mg milligram

Canada - English - Health Canada

merck frosst canada & cie, merck frosst canada & co. - cyproheptadine hydrochloride - syrup - 2mg - cyproheptadine hydrochloride 2mg - miscellaneous derivatives